UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000052291
Receipt number R000059285
Scientific Title The minimal clinically important change of the Fugl-Meyer Assessment lower extremity motor scale in patients with acute stroke.
Date of disclosure of the study information 2023/09/23
Last modified on 2024/11/25 13:24:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Minimal clinically important change in the assessment of lower limb motor function in people with acute stroke.

Acronym

MIC-FMALE in patients with stroke

Scientific Title

The minimal clinically important change of the Fugl-Meyer Assessment lower extremity motor scale in patients with acute stroke.

Scientific Title:Acronym

The MIC in FMA lower extremity motor score in patients with acute stroke

Region

Japan


Condition

Condition

stroke

Classification by specialty

Neurology Neurosurgery Rehabilitation medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the Minimal Clinically Important Change in the Fugl-Meyer Assessment lower extremity motor scale in patients with acute stroke.

Basic objectives2

Others

Basic objectives -Others

To investigate the cut-off points of the Fugl-Meyer Assessment lower extremity motor scale for clinically important values of other standardized assessment tools.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Fugl-Meyer Assessment Lower Extremity Motor Scale
Global rating scale of change (Patient perspective)
Global rating scale of change (Therapist perspective)

Key secondary outcomes

Short Physical Performance Battery
Functional Ambulation Categories
Trunk Control Test
Timed Up and Go test
Functional Independence Measure
Five sit to stand test


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

stroke (cerebral hemorrhage or cerebral infarction)

Key exclusion criteria

(1) Patients who have difficulty understanding instructions due to severe disturbance of consciousness
(2) Patients with a history of mental illness or severe cognitive decline
(3) Patients who have difficulty understanding instructions due to severe aphasia
(4) Patients with a history of locomotor or internal disorders that limit activities of daily living (ADL)
(5) Patients who did not give their consent
(6) Patients with FMA-LE motor score of 30 or higher at baseline

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Tetsuharu
Middle name
Last name Nakazono

Organization

Kiatasato University Hospital

Division name

Department of Rehabilitation

Zip code

252-0375

Address

1-15-1, Kitasato, Minami-ku, Sagamihara-city, Japan

TEL

0427788413

Email

ptnaka@kitasato-u.ac.jp


Public contact

Name of contact person

1st name Tetsuharu
Middle name
Last name Nakazono

Organization

KItasato University Hospital

Division name

Department of Rehabilitation

Zip code

252-0375

Address

1-15-1, Kitasato, Minami-ku, Sagamihara-city, Japan

TEL

0427788413

Homepage URL


Email

ptnaka@kitasato-u.ac.jp


Sponsor or person

Institute

Kitasato University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

KItasato University Hospital

Address

1-15-1,Kitasato,Minami-ku,Sagamihara,Japan

Tel

0427788413

Email

ptnaka@kitasato-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北里大学病院


Other administrative information

Date of disclosure of the study information

2023 Year 09 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2023 Year 09 Month 12 Day

Date of IRB

2023 Year 09 Month 27 Day

Anticipated trial start date

2023 Year 09 Month 29 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Study design: prospective single-center study

Data collection will start in September 2023. The present study includes a sample of convenience of patients hospitalized at the departments of rehabilitation in a university hospital in Japan speaking Japanese. Patients fulfilling inclusion criteria who agreed to participate will be included. The Fugl-Meyer assessment, Global rating scale of change (GRC), Short physical performance battery, Functional ambulation categories, Trunk control test, Functional independence measure Timed up and go test are employed.

Statistical analysis: The Receiver Operating Characteristic (ROC) curve will be used as a splitter to divide the participants into two groups: participants who present changes and participants who do not present changes in the FMA-LE scores based on the average on the GRC (patients and their therapist) which classified to be two groups of GRC < 6 or GRC > 5. The optimal MCID will be determined by the Youden index.

Sample size estimation: The COSMIN recommendation was the basis of the sample size estimation in this study. A sample size of 100 patients evaluated as "very good" was considered the minimum required sample size.


Management information

Registered date

2023 Year 09 Month 23 Day

Last modified on

2024 Year 11 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000059285